MX2009013220A - Induccion de fenotipo tolerogenico en las celulas dendriticas maduras. - Google Patents

Induccion de fenotipo tolerogenico en las celulas dendriticas maduras.

Info

Publication number
MX2009013220A
MX2009013220A MX2009013220A MX2009013220A MX2009013220A MX 2009013220 A MX2009013220 A MX 2009013220A MX 2009013220 A MX2009013220 A MX 2009013220A MX 2009013220 A MX2009013220 A MX 2009013220A MX 2009013220 A MX2009013220 A MX 2009013220A
Authority
MX
Mexico
Prior art keywords
dendritic cells
induction
mature dendritic
tolerogenic phenotype
binding molecule
Prior art date
Application number
MX2009013220A
Other languages
English (en)
Inventor
Maria Grazia Roncarolo
Jan E De Vries
Jose M Herrera Carballido
Ulf Korthaeuer
Silvia Adriana Gregori
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009013220A publication Critical patent/MX2009013220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

La presente invenci?n se refiere al uso de una mol?cula de enlace de CD45 para modular la funci?n de las c?lulas dendr?ticas. En particular, la presente invenci?n se refiere al uso de una mol?cula de enlace de CD45 para inducir a las c?lulas dendr?ticas tolerog?nicas, ?tiles en el tratamiento de enfermedades o trastornos, tales como enfermedades auto-inmunes y rechazo de trasplante.
MX2009013220A 2007-06-05 2008-06-03 Induccion de fenotipo tolerogenico en las celulas dendriticas maduras. MX2009013220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109672 2007-06-05
PCT/EP2008/056851 WO2008148761A1 (en) 2007-06-05 2008-06-03 Induction of tolerogenic phenotype in mature dendritic cells

Publications (1)

Publication Number Publication Date
MX2009013220A true MX2009013220A (es) 2010-04-09

Family

ID=39721982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013220A MX2009013220A (es) 2007-06-05 2008-06-03 Induccion de fenotipo tolerogenico en las celulas dendriticas maduras.

Country Status (17)

Country Link
US (1) US20100183602A1 (es)
EP (1) EP2160410A1 (es)
JP (1) JP2010529078A (es)
KR (1) KR20100035643A (es)
CN (1) CN101687928A (es)
AU (1) AU2008258646A1 (es)
BR (1) BRPI0812205A2 (es)
CA (1) CA2689570A1 (es)
CL (1) CL2008001620A1 (es)
EA (1) EA200901621A1 (es)
IL (1) IL202230A0 (es)
MA (1) MA31667B1 (es)
MX (1) MX2009013220A (es)
TN (1) TN2009000494A1 (es)
TW (1) TW200907061A (es)
WO (1) WO2008148761A1 (es)
ZA (1) ZA200908089B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
JP5926180B2 (ja) * 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
EP2305277A1 (en) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
PT2624873T (pt) 2010-10-06 2020-03-04 Harvard College Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
ES2878089T3 (es) 2011-04-28 2021-11-18 Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
WO2012149393A2 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
US20130058902A1 (en) * 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
EA201592103A3 (ru) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. Способы и композиции для усиления cd4+ регуляторных t-клеток
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
EP3411475A4 (en) 2016-02-06 2019-09-11 President and Fellows of Harvard College REGENERATION OF THE HEMATOPOIETIC NICHE TO RECONSTITUTE IMMUNITY
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CL2008001620A1 (es) 2009-02-20
AU2008258646A1 (en) 2008-12-11
CA2689570A1 (en) 2008-12-11
WO2008148761A1 (en) 2008-12-11
CN101687928A (zh) 2010-03-31
BRPI0812205A2 (pt) 2014-11-25
US20100183602A1 (en) 2010-07-22
ZA200908089B (en) 2010-07-28
IL202230A0 (en) 2010-06-16
EP2160410A1 (en) 2010-03-10
EA200901621A1 (ru) 2010-06-30
TN2009000494A1 (en) 2011-03-31
TW200907061A (en) 2009-02-16
KR20100035643A (ko) 2010-04-05
JP2010529078A (ja) 2010-08-26
MA31667B1 (fr) 2010-09-01

Similar Documents

Publication Publication Date Title
TN2009000494A1 (en) Induction of tolerogenic phenotype in mature dendritic cells
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
JO3266B1 (ar) متنوعات Fc الصامتة و الأجسام المضادة ضد CD40
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX2011010449A (es) Derivados de oxadiazol.
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
MY161415A (en) A homeopathic formulation
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013001612A (es) Moduladores de trpv3 novedosos.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX2010008668A (es) Composiciones fungicidas que comprenden 3'-bromo-2,3,4,6'-tetramet oxy-2'-6-dimetilbenzofenona.
WO2009058451A3 (en) Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
EP2471542A4 (en) THERAPEUTIC AGENT FOR HEPATIC DISEASES
WO2010115741A3 (en) New therapeutic approaches for treating neuroinflammatory conditions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal